At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Jul 9, 2026 at 20:30 ET
Mesoblast reported Q1 FY2026 EPS of -$0.07, missing consensus of -$0.03 by 133%. However, the company announced full-year Ryoncil net revenue of $115M, exceeding initial projections, with continued growth expected. The EPS miss is on a tiny base and the Ryoncil revenue narrative is the dominant driver, making the overall tone mixed.
- FY2026 Q1 EPS: -$0.07, -133% miss vs consensus -$0.03.
- Ryoncil net revenue of US$36M for Q1 FY2026 and US$115M for full year ended June 30, 2026.
- CEO stated revenue exceeded initial projections and anticipates continued growth.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access